Targets › AKR1B1
3 programs from 3 companies in 3 trials: 2 Phase 2, 1 Phase 3; Neurology, Metabolic and endocrine; next expected readout Dec 2026.
Catalyzes the NADPH-dependent reduction of a wide variety of carbonyl-containing compounds to their corresponding alcohols. Displays enzymatic activity towards endogenous metabolites such as aromatic and aliphatic aldehydes, ketones, monosaccharides, bile acids and xenobiotics substrates. (UniProt, P15121)
Open in Phaseline: the race on AKR1B1, likelihood bands and readouts
| Company | Drug | Targets | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|---|
| Applied Therapeutics | Caficrestat (AT-001) Aldose reductase inhibitor | AKR1B1 | Phase 3 | Diabetic Cardiomyopathies | – |
| Arctic Therapeutics | Caficrestat (NPI-001) Aldose reductase inhibitor | AKR1B1 | Phase 2 | Hereditary Cystatin C Amyloid Angiopathy (HCCAA) | Dec 2026 |
| St. John's Research Institute | Epalrestat Aldose reductase inhibitor | AKR1B1 | Phase 2 | Diabetic Neuropathy Peripheral | – |
Hereditary Cystatin C Amyloid Angiopathy (HCCAA) (1) Diabetic Neuropathy Peripheral (1) Diabetic Cardiomyopathies (1)
small molecule (3)
Arctic Therapeutics (1) St. John's Research Institute (1) Applied Therapeutics (1)
–
Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.